{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:20:14Z","timestamp":1772850014856,"version":"3.50.1"},"reference-count":16,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2018]]},"DOI":"10.5582\/ddt.2017.01069","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T22:12:52Z","timestamp":1519510372000},"page":"51-54","source":"Crossref","is-referenced-by-count":28,"title":["Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report"],"prefix":"10.5582","volume":"12","author":[{"given":"Shunsuke","family":"Kiuchi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Hisatake","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kabuki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenobu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-234."},{"key":"2","unstructured":"2. Baena-D\u00edez JM, Pe\u00f1afiel J, Subirana I, <i>et al<\/i>. Risk of cause-specific death in individuals with diabetes: A competing risks analysis. Diabetes Care. 2016; 39:1987-1995."},{"key":"3","unstructured":"3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117-2128."},{"key":"4","unstructured":"4. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, J\u00f8rgensen ME, Thuresson M, Arya N, Bodeg\u00e5rd J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017; 136:249-259."},{"key":"5","unstructured":"5. Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, Ikeda T. Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction. Clin Exp Hypertens. 2017; 39:350-354."},{"key":"6","unstructured":"6. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruysse F, Meininger G, Matthews D. Rationale, design, and baseline characteristics of the Canaglyflozin Cardiovascular Assessment Study (CANVAS) \u2013 A randomized placebocontrolled trial. Am Heart J. 2013; 166:217-223."},{"key":"7","unstructured":"7. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375:323- 334."},{"key":"8","unstructured":"8. Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK, Rosenthal N, de Zeeuw D, Matthews DR; CANVAS Program Collaborative Group. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CAMVAS and CANVAS-R trials. Diabetes Obes Metab. 2017; 19:926-935."},{"key":"9","unstructured":"9. Martens P, Mathieu C, Verbrugge FH. Promise of SGLT2 inhibitors in heart failure: Diabetes and beyond. Curr Treat Options Cardiovasc Med. 2017; 19:23."},{"key":"10","unstructured":"10. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015; 38:420- 428."},{"key":"11","unstructured":"11. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ. Sodium glucose cotransporter-2 inhibition in heart failure: Potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017; 136:1643- 1658."},{"key":"12","unstructured":"12. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Th\u00e9venet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015; 21:512-517."},{"key":"13","unstructured":"13. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014; 26:148."},{"key":"14","unstructured":"14. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation. 2002; 105:1727-1733."},{"key":"15","unstructured":"15. Matyal R, Sakamuri S, Huang T, Owais K, Parikh S, Khabbaz K, Wang A, Sellke F, Mahmood F. Oxidative stress and nerve function after cardiopulmonary bypass in patients with diabetes. Ann Thorac Surg. 2014; 98:1635- 1643."},{"key":"16","unstructured":"16. Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. <sup>123<\/sup>I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: The ADMIREHFX study. J Nucl Med. 2015; 56:1011-1018."}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/12\/1\/12_2017.01069\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T05:23:53Z","timestamp":1521869033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/12\/1\/12_2017.01069\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2017.01069","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}